{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:18:12Z","timestamp":1792721892226,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jvs.2025.05.037","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T06:37:07Z","timestamp":1749191827000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7945-4133","authenticated-orcid":false,"given":"Catherine C.","family":"Go","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8423-4119","authenticated-orcid":false,"given":"Frank","family":"Annie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-9251","authenticated-orcid":false,"given":"Kerry","family":"Drabish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-5550","authenticated-orcid":false,"given":"Mohammad H.","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2025.05.037_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2024.1517265","article-title":"Novel antidiabetic therapies in patients with peripheral artery disease: current perspective","volume":"5","author":"Jani\u0107","year":"2024","journal-title":"Front Clin Diabetes Healthc"},{"key":"10.1016\/j.jvs.2025.05.037_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.peptides.2018.09.002","article-title":"Glucagon-like peptide-1 receptor action in the vasculature","volume":"111","author":"Almutairi","year":"2019","journal-title":"Peptides"},{"key":"10.1016\/j.jvs.2025.05.037_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6820377","article-title":"Potential roles of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in nondiabetic populations","volume":"2022","author":"Xu","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jvs.2025.05.037_bib4","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2025.05.037_bib5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2025.05.037_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2025.05.037_bib7","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvs.2025.05.037_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jvs.2025.05.037_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.jvs.2025.05.037_bib10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.metabol.2013.04.010","article-title":"GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways","volume":"62","author":"Aronis","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.jvs.2025.05.037_bib11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jvs.2025.05.037_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112083","article-title":"Tirzepatide and major adverse limb events: insights from a multicenter real-world analysis in PAD and diabetes patients","volume":"222","author":"Wu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jvs.2025.05.037_bib13","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2025.05.037_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ehjcvp\/pvae071","article-title":"Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes","volume":"10","author":"Bonaca","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jvs.2025.05.037_bib15","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jvs.2025.05.037_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/14791641251322909","article-title":"The impact of semaglutide on wound healing in diabetes related foot ulcer patients: a TriNetX database study","volume":"22","author":"Lewis","year":"2025","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jvs.2025.05.037_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1545","article-title":"Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral artery disease: the STARDUST randomized clinical trial","volume":"7","author":"Caruso","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521425011127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521425011127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:52:31Z","timestamp":1755132751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521425011127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":17,"alternative-id":["S0741521425011127"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2025.05.037","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2025.05.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Society for Vascular Surgery. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}